Expert consensus on clinical pathway of percutaneous renal denervation therapy for hypertension in China(2025)
10.3969/j.issn.1004-8812.2025.09.001
- VernacularTitle:经皮去肾神经术治疗高血压临床路径中国专家共识(2025版)
- Author:
China Heart HOUSE
;
Yu-jie ZHOU
;
Ning-ling SUN
;
Wei-min WANG
;
Jun-bo GE
- Collective Name:National Clinical Research Center for Interventional Medicine;Expert Group of Expert Consensus on Clinical Pathway of Percutaneous Renal Denervation Therapy for Hypertension in China
- Publication Type:Journal Article
- Keywords:
Renal denervation;
Hypertension;
Clinical pathway;
Expert consensus
- From:
Chinese Journal of Interventional Cardiology
2025;33(9):481-490
- CountryChina
- Language:Chinese
-
Abstract:
Percutaneous renal denervation(RDN)is a minimally invasive interventional treatment for hypertension that has been used in clinics at home and abroad,primarily for patients with resistant hypertension or who cannot tolerate antihypertensive drugs.Current clinical studies have confirmed the safety and efficacy of this technique.As RDN is still in its promotional and popularization stage,the expert group has written this clinical pathway to promote the orderly implementation of this technology,standardize the operating process,and standardize diagnostic and therapeutic behaviors.The pathway describes the clinical assessment of patients in detail(including indications,contraindications,and the patient screening process),the standardized operating process for RDN(including perioperative medication,anaesthesia,ablation,and management of complications),and the postoperative follow-up plan(including follow-up content,methods,and timing).It is hoped that this will serve as a reference for physicians involved in RDN clinical work,standardize diagnostic and therapeutic behaviors,and promote the standardized,precise,and sustainable development of the RDN discipline.
